Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) derived from HAdV with naturally low rates of pre-existing immunity will be beneficial for future clinical translation. We generated a low-seroprevalence HAdV-D10 serotype vector incorporating an αvβ6 integrin-selective peptide, A20, to target αvβ6-positive tumor cell types. HAdV-D10 has limited natural tropism. Structural and biological studies of HAdV-D10 knob protein highlighted low-affinity engagement with native adenoviral receptors CAR and sialic acid. HAdV-D10 fails to engage blood coagulation factor X, potentially eliminating "off-target" hepatic sequestration in vivo. We engineered an A20 peptide that selectively binds αvβ6 integrin into the DG loop of HAdV-D10 fiber knob. Assays in αvβ6+ cancer cell lines demonstrated significantly increased transduction mediated by αvβ6-targeted variants compared with controls, confirmed microscopically. HAdV-D10.A20 resisted neutralization by neutralizing HAdV-C5 sera. Systemic delivery of HAdV-D10.A20 resulted in significantly increased GFP expression in BT20 tumors. Replication-competent HAdV-D10.A20 demonstrated αvβ6 integrin-selective cell killing in vitro and in vivo. HAdV-D10 possesses characteristics of a promising virotherapy, combining low seroprevalence, weak receptor interactions, and reduced off-target uptake. Incorporation of an αvβ6 integrin-selective peptide resulted in HAdV-D10.A20, with significant potential for clinical translation.

Department of Genetics and Microbiology Faculty of Science Charles University Viničná 5 128 44 Prague 2 Czech Republic

Division of Cancer and Genetics School of Medicine Cardiff University Heath Park Cardiff CF14 4XN UK

Division of Infection and Immunity School of Medicine Cardiff University Heath Park Cardiff CF14 4XN UK

Division of Molecular Biology Ruđer Bošković Institute Bijenička cesta 54 10000 Zagreb Croatia

European Cancer Stem Cell Research Institute Cardiff University Cardiff CF24 4HQ UK

Velindre Cancer Centre Whitchurch Cardiff CF14 2TL UK

See more in PubMed

Ghebremedhin B. Human adenovirus: viral pathogen with increasing importance. Eur. J. Microbiol. Immunol. (Bp) 2014;4:26–33. PubMed PMC

Russell W.C. Adenoviruses: update on structure and function. J. Gen. Virol. 2009;90:1–20. PubMed

HAdV Working Group. http://hadvwg.gmu.edu/

Gaggar A., Shayakhmetov D.M., Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 2003;9:1408–1412. PubMed

Wang H., Li Z., Liu Y., Persson J., Beyer I., Möller T., Koyuncu D., Drescher M.R., Strauss R., Zhang X.-B., et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14. Nat. Med. 2011;17:96–104. PubMed PMC

Robinson C.M., Seto D., Jones M.S., Dyer D.W., Chodosh J. Molecular evolution of human species D adenoviruses. Infect. Genet. Evol. 2011;11:1208–1217. PubMed PMC

Baker A.T., Mundy R.M., Davies J.A., Rizkallah P.J., Parker A.L. Human adenovirus type 26 uses sialic acid–bearing glycans as a primary cell entry receptor. Sci. Adv. 2019;5:eaax3567. PubMed PMC

Arnberg N., Kidd A.H., Edlund K., Nilsson J., Pring-Akerblom P., Wadell G. Adenovirus type 37 binds to cell surface sialic acid through a charge-dependent interaction. Virology. 2002;302:33–43. PubMed

Persson B.D., John L., Rafie K., Strebl M., Frängsmyr L., Ballmann M.Z., Mindler K., Havenga M., Lemckert A., Stehle T., et al. Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46. Proc. Natl. Acad. Sci. U S A. 2021;118 e2020732118. PubMed PMC

Wold W.S.M., Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr. Gene Ther. 2013;13:421–433. PubMed PMC

Lemos de Matos A., Franco L.S., McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Mol. Ther. Methods Clin. Dev. 2020;17:349–358. PubMed PMC

Wickham T.J., Mathias P., Cheresh D.A., Nemerow G.R. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309–319. PubMed

Cohen C.J., Shieh J.T., Pickles R.J., Okegawa T., Hsieh J.T., Bergelson J.M. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc. Natl. Acad. Sci. U S A. 2001;98:15191–15196. PubMed PMC

Sachs M.D., Rauen K.A., Ramamurthy M., Dodson J.L., De Marzo A.M., Putzi M.J., Schoenberg M.P., Rodriguez R. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology. 2002;60:531–536. PubMed

Korn W.M., Macal M., Christian C., Lacher M.D., McMillan A., Rauen K.A., Warren R.S., Ferrell L. Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Ther. 2006;13:792–797. PubMed

Parker A.L., Waddington S.N., Nicol C.G., Shayakhmetov D.M., Buckley S.M., Denby L., Kemball-Cook G., Ni S., Lieber A., McVey J.H., et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood. 2006;108:2554–2561. PubMed

Waddington S.N., McVey J.H., Bhella D., Parker A.L., Barker K., Atoda H., Pink R., Buckley S.M.K., Greig J.A., Denby L., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132:397–409. PubMed

Kalyuzhniy O., Di Paolo N.C., Silvestry M., Hofherr S.E., Barry M.A., Stewart P.L., Shayakhmetov D.M. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U S A. 2008;105:5483–5488. PubMed PMC

Knowles M.R., Hohneker K.W., Zhou Z., Olsen J.C., Noah T.L., Hu P.C., Leigh M.W., Engelhardt J.F., Edwards L.J., Jones K.R. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 1995;333:823–831. PubMed

Kuriyama S., Tominaga K., Kikukawa M., Nakatani T., Tsujinoue H., Yamazaki M., Nagao S., Toyokawa Y., Mitoro A., Fukui H. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res. 1998;18:2345–2351. PubMed

Molnar-Kimber K.L., Sterman D.H., Chang M., Kang E.H., ElBash M., Lanuti M., Elshami A., Gelfand K., Wilson J.M., Kaiser L.R., et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 1998;9:2121–2133. PubMed

Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Béthune M.-P., Kostense S., Penders G., Helmus N., Koudstaal W., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 2003;77:8263–8271. PubMed PMC

Parker A.L., Waddington S.N., Buckley S.M.K., Custers J., Havenga M.J.E., van Rooijen N., Goudsmit J., McVey J.H., Nicklin S.A., Baker A.H. Effect of neutralizing sera on factor X-mediated adenovirus serotype 5 gene transfer. J. Virol. 2009;83:479–483. PubMed PMC

Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999;6:1574–1583. PubMed

Lynch J.P., Kajon A.E. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin. Respir. Crit. Care Med. 2016;37:586–602. PubMed PMC

Uusi-Kerttula H., Davies J.A., Thompson J.M., Wongthida P., Evgin L., Shim K.G., Bradshaw A., Baker A.T., Rizkallah P.J., Jones R., et al. Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clin. Cancer Res. 2018;24:4215–4224. PubMed

Jakubczak J.L., Rollence M.L., Stewart D.A., Jafari J.D., Von Seggern D.J., Nemerow G.R., Stevenson S.C., Hallenbeck P.L. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J. Virol. 2001;75:2972–2981. PubMed PMC

Kirby I., Davison E., Beavil A.J., Soh C.P., Wickham T.J., Roelvink P.W., Kovesdi I., Sutton B.J., Santis G. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J. Virol. 2000;74:2804–2813. PubMed PMC

Nicklin S.A., Seggern D.J.V., Work L.M., Pek D.C., Dominiczak A.F., Nemerow G.R., Baker A.H. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol. Ther. 2001;4:534–542. PubMed

Santis G., Legrand V., Hong S.S., Davison E., Kirby I., Imler J.L., Finberg R.W., Bergelson J.M., Mehtali M., Boulanger P. Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. J. Gen. Virol. 1999;80:1519–1527. PubMed

DiCara D., Burman A., Clark S., Berryman S., Howard M.J., Hart I.R., Marshall J.F., Jackson T. Foot-and-Mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin αvβ6: implications for infectiousness. J. Virol. 2008;82:1537–1546. PubMed PMC

Uusi-Kerttula H., Davies J., Coughlan L., Hulin-Curtis S., Jones R., Hanna L., Chester J.D., Parker A.L. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget. 2016;7:27926–27937. PubMed PMC

Stella Man Y.K., Foster J., Carapuça E., Davies J.A., Parker A.L., Sosabowski J., Halldén G. Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Sci. Rep. 2019;9:12840. PubMed PMC

Man Y.K.S., Davies J.A., Coughlan L., Pantelidou C., Blázquez-Moreno A., Marshall J.F., Parker A.L., Halldén G. The novel oncolytic adenoviral mutant ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Mol. Cancer Ther. 2018;17:575–587. PubMed

Coughlan L., Vallath S., Saha A., Flak M., McNeish I.A., Vassaux G., Marshall J.F., Hart I.R., Thomas G.J. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J. Virol. 2009;83:6416–6428. PubMed PMC

Whilding L.M., Parente-Pereira A.C., Zabinski T., Davies D.M., Petrovic R.M.G., Kao Y.V., Saxena S.A., Romain A., Costa-Guerra J.A., Violette S., et al. Targeting of aberrant αvβ6 integrin expression in solid tumors using chimeric antigen receptor-engineered T cells. Mol. Ther. 2017;25:259–273. PubMed PMC

Ahmed N., Pansino F., Clyde R., Murthi P., Quinn M.A., Rice G.E., Agrez M.V., Mok S., Baker M.S. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis. 2002;23:237–244. PubMed

Katoh D., Nagaharu K., Shimojo N., Hanamura N., Yamashita M., Kozuka Y., Imanaka-Yoshida K., Yoshida T. Binding of αvβ1 and αvβ6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells. Oncogenesis. 2013;2:e65. PubMed PMC

Sun Q., Sun F., Wang B., Liu S., Niu W., Liu E., Peng C., Wang J., Gao H., Liang B., et al. Interleukin-8 promotes cell migration through integrin αvβ6 upregulation in colorectal cancer. Cancer Lett. 2014;354:245–253. PubMed

Bates R.C., Bellovin D.I., Brown C., Maynard E., Wu B., Kawakatsu H., Sheppard D., Oettgen P., Mercurio A.M. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 2005;115:339–347. PubMed PMC

Tod J., Hanley C.J., Morgan M.R., Rucka M., Mellows T., Lopez M.-A., Kiely P., Moutasim K.A., Frampton S.J., Sabnis D., et al. Pro-migratory and TGF-β-activating functions of αvβ6 integrin in pancreatic cancer are differentially regulated via an Eps8-dependent GTPase switch. J. Pathol. 2017;243:37–50. PubMed PMC

Brown N.F., Marshall J.F. Integrin-mediated TGFβ activation modulates the tumour microenvironment. Cancers. 2019;11:1221. PubMed PMC

Darougar S., Walpita P., Thaker U., Viswalingam N., Gardner L., McSwiggan D.A. Adenovirus serotypes isolated from ocular infections in London. Br. J. Ophthalmol. 1983;67:111–114. PubMed PMC

Zografos L. [Keractoconjunctivitis caused by type 10 adenovirus] Ophthalmologica. 1977;174:61–64. PubMed

Huebner R.J., Rowe W.P. Adenoviruses as etiologic agents in conjunctivitis and Keratoconjunctivitis. Am. J. Ophthalmol. 1957;43:20–25. PubMed

Baker A.T., Greenshields-Watson A., Coughlan L., Davies J.A., Uusi-Kerttula H., Cole D.K., Rizkallah P.J., Parker A.L. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nat. Commun. 2019;10:741. PubMed PMC

Duffy M.R., Alonso-Padilla J., John L., Chandra N., Khan S., Ballmann M.Z., Lipiec A., Heemskerk E., Custers J., Arnberg N., et al. Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56. J. Gen. Virol. 2018;99:135–147. PubMed

Nevels M., Spruss T., Wolf H., Dobner T. The adenovirus E4orf6 protein contributes to malignant transformation by antagonizing E1A-induced accumulation of the tumor suppressor protein p53. Oncogene. 1999;18:9–17. PubMed

Havenga M., Vogels R., Zuijdgeest D., Radosevic K., Mueller S., Sieuwerts M., Weichold F., Damen I., Kaspers J., Lemckert A., et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J. Gen. Virol. 2006;87:2135–2143. PubMed

Alba R., Bradshaw A.C., Parker A.L., Bhella D., Waddington S.N., Nicklin S.A., van Rooijen N., Custers J., Goudsmit J., Barouch D.H., et al. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood. 2009;114:965–971. PubMed PMC

Hara J., Ishibashi T., Fujimoto F., Danjyo S., Minekawa Y., Maeda A. Adenovirus type 10 Keratoconjunctivitis with increased intraocular pressure. Am. J. Ophthalmol. 1980;90:481–484. PubMed

Carlisle R.C., Di Y., Cerny A.M., Sonnen A.F.-P., Sim R.B., Green N.K., Subr V., Ulbrich K., Gilbert R.J.C., Fisher K.D., et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113:1909–1918. PubMed PMC

Bradshaw A.C., Coughlan L., Miller A.M., Alba R., van Rooijen N., Nicklin S.A., Baker A.H. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. J. Control Release. 2012;164:394–402. PubMed PMC

Stanton R.J., McSharry B.P., Armstrong M., Tomasec P., Wilkinson G.W.G. Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques. 2008;45:659–668. PubMed

Bates E.A., Counsell J.R., Alizert S., Baker A.T., Suff N., Boyle A., Bradshaw A.C., Waddington S.N., Nicklin S.A., Baker A.H., et al. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses. 2021;13:1483. PubMed PMC

Nestić, D., Uil, T.G., Ma, J., Roy, S., Vellinga, J., Baker, A.H., Custers, J., and Majhen, D. αvβ3 integrin is required for efficient infection of epithelial cells with human adenovirus type 26. J. Virol. 93, e01474-18. PubMed PMC